Stefanos Theoharis
Chief Executive Officer bij Onechain Immunotherapeutics
Oorsprong van het eerstegraads netwerk van Stefanos Theoharis
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Onechain Immunotherapeutics
Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany.
5
| Holding Company | Medical Specialties | 5 |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany.
2
| Holding Company | Biotechnology | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Stefanos Theoharis via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Colorado State University | College/University | Masters Business Admin | |
Instituto de Empresa SL | College/University | Masters Business Admin | |
Ruprecht-Karls-Universität Heidelberg | College/University | Corporate Officer/Principal | |
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Corporate Officer/Principal | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chief Operating Officer | |
Janssen, Inc.
Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer |
Statistieken
Internationaal
Verenigde Staten | 4 |
Verenigd Koninkrijk | 3 |
Spanje | 3 |
Duitsland | 2 |
Frankrijk | 2 |
Sectoraal
Health Technology | 7 |
Consumer Services | 5 |
Operationeel
Corporate Officer/Principal | 7 |
Director/Board Member | 5 |
Chief Tech/Sci/R&D Officer | 4 |
Masters Business Admin | 2 |
Chief Operating Officer | 1 |
Sterkste connecties
Insiders | |
---|---|
Eugen Leo | 6 |
Michel Janicot | 5 |
Jorge Alemany | 4 |
Pablo Menéndez | 1 |
Albert Carreras | 1 |
Albert Ferrer | 1 |
Laura Rodriguez | 1 |
- Beurs
- Insiders
- Stefanos Theoharis
- Bedrijfsconnecties